Clinical value of plasma and peripheral blood mononuclear cells Epstein–Barr Virus DNA dynamics on prognosis of allogeneic stem cell transplantation

• DOI: 10.3389/fcimb.2022.980113
• Publication Date: 2022-09-16T05:07:27Z
• Authors: Xi Zhou; Xuan Lu; Jing He; Ziwei Xu; Qian Li; Pian Ye; Zhaodong Zhong; Wei Shi; Han Yan; Yong You; Yu Hu; Huafang Wang
• Keywords: Dynamics

The application of intracellular and extracellular Epstein-Barr virus (EBV) DNA in allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been poorly characterized. We conducted a combined prospective-retrospective study 300 patients who underwent allo-HSCT between 2016 to 2019 our center monitored for EBV within the first year after HSCT. Combining optimal cut-off value load (7.3×104 copies/106 cells) peripheral blood mononuclear cells (PBMCs) qualitative detection plasma (400 copies/mL) allowed better differentiation EBV-related posttransplant lymphoproliferative disorders (EBV-PTLD), with increased sensitivity (100%) specificity (86%), provided effective risk stratification level according their impact on transplant outcomes. By multivariate analysis, intermediate-level (low PBMCs or high but negative plasma) was associated superior overall survival (HR 1.92, 95% CI 1.03-3.57, p=0.039) lower transplant-related mortality 3.35, 1.31-8.58, p=0.012) compared those high-level (high positive plasma). Notably, EBV-level group had poor reconstitution CD4+ CD8+T cells, both low groups showed abnormally increase IL-10 one year. Additionally, peak during 3-12 months higher incidence chronic graft versus host disease (GVHD) than 3 post (17.4% vs 13.7%, p=0.029). Collectively, can synergistically predict EBV-PTLD GVHD. presented might contribute T favorable prognosis allo-HSCT.